Synchrony appoints Deborah Ellinger to board of directors

STAMFORD, Conn. - Synchrony Financial (NYSE:SYF), a $27.27 billion market cap financial services company with a "GREAT" financial health score according to InvestingPro, announced Monday the appointment of Deborah Ellinger to its Board of Directors, effective October 1, 2025.

Ellinger, who currently serves as a senior advisor with Boston Consulting Group (BCG), brings experience from the health and wellness, retail, and pet industries to the consumer financial services company. At BCG, she primarily works with private equity clients investing in consumer and retail companies.

From 2004 to 2018, Ellinger held CEO and presidential roles at four private-equity-backed companies, including Ideal Image, The Princeton Review, Restoration Hardware, and Wellness Pet Food. She currently serves on the board of directors of Chewy, Inc., an online pet retailer.

"Deborah has extensive cross-sector experience, including health and wellness and pet, that is well aligned with our strategic priorities and focus areas," said Brian Doubles, President and Chief Executive Officer of Synchrony, in a press release statement.

Ellinger expressed her enthusiasm about the appointment, stating, "The Company is committed to driving the best outcomes for all of its stakeholders, and I look forward to supporting this commitment as a member of the Board."

With Ellinger’s appointment, Synchrony’s Board of Directors will expand to twelve members.

Synchrony provides consumer financing services, credit and banking products to consumers, and supports businesses across various sectors including retail, health, and automotive.

In other recent news, Synchrony Financial has seen a series of notable developments. The company announced a new partnership with Audibel, offering financing options for hearing care services and devices across Audibel’s extensive network of over 1,000 locations nationwide. This collaboration will utilize Synchrony’s CareCredit credit card and installment loan solutions, providing patients with flexible payment options for hearing exams, devices, and accessories.

Additionally, Synchrony Financial’s stock has received increased price targets from several analyst firms. JMP Securities raised its price target to $88, citing positive management commentary and strong credit results. BofA Securities also increased its price target to $84, attributing the rise to anticipated loan growth and a revised price-to-earnings multiple. Furthermore, Synchrony Financial has released its monthly charge-off and delinquency statistics for the thirteen months ended July 31, 2025, and plans to continue providing these updates regularly. These recent developments reflect a dynamic period for Synchrony Financial, with strategic partnerships and positive analyst outlooks.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.